Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of CYP2D6 Genetic Polymorphism on the Vulnerability to Drug-drug Interactions With Tramadol: a Gene-environment Interaction and Phenoconversion Study on Patients Undergoing a Steady Treatment With a Potent CYP2D6 Inhibitor.

NCT04249674 is registered in ClinicalTrials.gov with University Hospital, Geneva as lead sponsor.

NCT NCT04249674
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04249674 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of CYP2D6 Genetic Polymorphism on the Vulnerability to Drug-drug Interactions With Tramadol: a Gene-environment Interaction and Phenoconversion Study on Patients Undergoing a Steady Treatment With a Potent CYP2D6 Inhibitor.
Lead sponsor
University Hospital, Geneva
Phase
Observational
Overall status
Unknown status
Start date
November 4, 2019
Completion date
December 31, 2022
Enrollment
172 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

interaction, pain